image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Pre Registered 
 Hotel Info 
 Abstracts 
 Scientific Program 
 Social Program 
 Exhibition 
 Contact Us 
 Archive 
       XXIII Annual Congress of the Iranian Society of Ophthalmology        بـیــست و سومین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Topical Interferon Alpha 2b in the Treatment of Vernal Keratoconjunctivitis
Author(s): Habibollah Zanjani MD; Alireza Maleki MD; Abdolhossein Ghafourian MD; Mojtaba Abrishami MD
Presentation Type: Oral
Subject: Cornea and Anterior Segment
Others:
Presenting Author:
Name: Habibollah Zanjani
Affiliation :(optional) alzahra eye hospital - zahedan
E mail: zanjanih@zaums.ac.ir
Phone: 3224991
Mobile: 09115410911
Purpose:

To evaluate the efficacy and safety of a 2-month topical interferon alpha 2b (IFN-α2b) treatment in patients with moderate to severe and refractory vernal keratoconjunctivitis (VKC).

Methods:

In an observational case series study, 15 individuals (12 males, 3 females), 6 to 25 years having bilateral VKC were included. Exclusion criteria were history of any intraocular or corneal disease, anomaly or surgery. Patients received topical treatment with one million IU/mL interferon alpha 2b, 4 times a day for 2 months. Each patient was evaluated at before and 2, 4, 6 and 8 weeks after the treatment initiation. Subjective and objective scores were evaluated at the baseline and at the follow ups. Descriptive analysis and paired-samples t test were used for statistical analysis.

Results:

No significant complications or side effects associated with the use of topical interferon alpha 2b were observed. Symptom scores for itching, tearing, photophobia, redness, foreign body sensation and total symptom score for corneal lesions, papillary hypertrophy, limbal hyperemia, limbal hypertrophy, corneal PEE, and total examination score significantly improved during the 2-month treatment.

Conclusion:

Administration of topical IFN-α2b alleviated VKC symptoms and signs. IFN-α2b can be recommended as an effective and safe therapy for moderate to severe and refractory VKC.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        ارسال مقالات
        برنامه کنگره
        برنامه های جانبی
        نمایشگاه
        تماس با ما
        آرشیو کنگره سالهای گذشته
        جستجوی سخنران
 
Last News

  - بـیــست و سومین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران